If you have been reading about cyclic heptapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular mass | About 1024.2 g/mol | Monoisotopic value for the free base |
| Appearance | White to off-white lyophilized powder | Visual inspection is not an identity test |
| Solubility | Soluble in water and polar organic solvents | Dissolution depends on salt form and pH |
| Typical storage | -20 °C, dry, protected from light | Powder is more stable than prepared solutions |
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Pompe disease has an autosomal recessive inheritance pattern. This means the defective gene is located on an autosome, and two faulty copies of the gene—one from each parent—are required to be born with the disorder. As with all cases of autosomal recessive inheritance, children have a one in four chance of inheriting the disorder when both parents carry the defective gene, and although both parents carry one copy of the defective gene, they are usually unaffected by the disorder. The disease is caused by a mutation in a gene (acid alpha-glucosidase: also known as acid maltase) on the long arm of chromosome 17 at 17q25.2-q25.3 (base pair 75,689,876 to 75,708,272). The number of mutations described is currently (in 2010) 289 with 67 being non-pathogenic mutations and 197 pathogenic mutations. The remainder are still being evaluated for their association with disease. The gene spans approximately 20 kb and contains 20 exons with the first exon being noncoding. The coding sequence of the putative catalytic site domain is interrupted in the middle by an intron of 101 bp. The promoter has features characteristic of a housekeeping gene. The GC content is high (80%) and distinct TATA and CCAAT motifs are lacking. Most cases appear to be due to three mutations. A transversion (T → G) mutation is the most common among adults with this disorder. This mutation interrupts a site of RNA splicing. The gene encodes a protein—acid alpha-glucosidase (EC 3.2.1.20)—which is a lysosomal hydrolase.
== Reactions == Meirav Ben-Ari, an Israeli Knesset member, stated, "The children in Gaza brought it upon themselves." Far-right Israeli Nation Security Minister Itamar Ben-Gvir called for the death of any child or woman who got too close to the border during a debate with Israeli military chief Herzi Halevi, claiming that "We cannot have women and children getting close to the border... anyone who gets near must get a bullet [in the head],". Ben-Gvir claimed that the open-fire policy he was advocating for was based on the perceived use of women and children by Hamas to target Israel. During an interview on Israeli television, a former Mossad official Rami Igra who had headed the agencies "Captive and Missing Division", claimed that there were no uninvolved civilians in Gaza. He raised claims that "anyone over four is a Hamas supporter" and that only those under four could be considered children, while anyone above that age could starve. Rabbi Eliyahu Mali, the head of a yeshiva in Jaffa, stated that the ongoing war was a mitzvah war and that not a soul shall live in Gaza as they will all grow up to become Hamas. When asked about babies and children in context with his comments, he stated; "Babies too?...The same thing. You can't be clever with the Torah. Today he's a baby, tomorrow he's a fighter. There are no questions here. Today's terrorists were 8-year-old children in the previous operation. So you can't To be satisfied here.
== Gingival fibers and periodontitis == In theory, gingival fibers are the protectors against periodontitis, as once they are breached, they cannot be regenerated. When destroyed, the gingival sulcus (labelled G in the diagram) increases in depth apically, allowing more debris and bacteria to remain in intimate contact with the delicate sulcular and junctional epithelia for longer times.
Sources: en.wikipedia.org
==== Membrane-introduction mass spectrometry: measuring gases in solution ==== Membrane-introduction mass spectrometry combines the isotope ratio mass spectrometry with a reaction chamber/cell separated by a gas-permeable membrane. This method allows the study of gases as they evolve in solution. This method has been extensively used for the study of the production of oxygen by Photosystem II.
Porous silicon (abbreviated as "PS" or "pSi") is a form of the chemical element silicon that has introduced nanopores in its microstructure, rendering a large surface to volume ratio in the order of 500 m2/cm3.
Acetyl-CoA can be metabolized through the TCA cycle in any cell, but it can also undergo ketogenesis in the mitochondria of liver cells. When glucose availability is low, oxaloacetate is diverted away from the TCA cycle and is instead used to produce glucose via gluconeogenesis. This utilization of oxaloacetate in gluconeogenesis can make it unavailable to condense with acetyl-CoA, preventing entrance into the TCA cycle. In this scenario, energy can be harvested from acetyl-CoA through ketone production. In ketogenesis, two acetyl-CoA molecules condense to form acetoacetyl-CoA via thiolase. Acetoacetyl-CoA briefly combines with another acetyl-CoA via HMG-CoA synthase to form hydroxy-β-methylglutaryl-CoA. Hydroxy-β-methylglutaryl-CoA form the ketone body acetoacetate via HMG-CoA lyase. Acetoacetate can then reversibly convert to another ketone body—D-β-hydroxybutyrate—via D-β-hydroxybutyrate dehydrogenase. Alternatively, acetoacetate can spontaneously degrade to a third ketone body (acetone) and carbon dioxide, which generates much greater concentrations of acetoacetate and D-β-hydroxybutyrate. The resulting ketone bodies cannot be used for energy by the liver so are exported from the liver to supply energy to the brain and peripheral tissues. In addition to fatty acids, deaminated ketogenic amino acids can also be converted into intermediates in the citric acid cycle and produce ketone bodies.
Arthur delivers the oil and considers having Sally join his escape, but he changes his mind and leaves when she tells him about Gwen. Determined to flee Wellington Wells with Gwen, Sally plans to steal General Byng's personal motorboat hidden near his military base. She convinces Dr. Helen Faraday (Samantha Lee) to create a new engine for the boat but fails to steal the key, getting knocked out by a sleeping dart trap. She awakens to find herself with General Byng in his safehouse; Byng intends to keep Sally imprisoned there until the problems in Wellington Wells are resolved while sending Gwen away to the mainland. Sally refuses, fights Byng, takes the key to the boat, and locks him inside the safehouse. Sally sneaks Gwen to the boat at night and rides it out of Wellington Wells. Ollie's Story: Ollie Starkey (Allan James Cooke) is a former British Army soldier, who lives as a recluse at his fortified hideout in the Garden District. His only company is a talking hallucination of his daughter, Margaret (Eloise Webb), killed years ago during the Very Bad Thing. After helping Arthur along his journey and having his hideout destroyed by Wastrels, he finds his former commander, General Byng. He informs him of the papier-mâché tanks Arthur had discovered. Byng reveals that he knew about the fake tanks but remained quiet to avoid a rebellion, which he doubts would have been successful. He also reveals that Ollie knew about the tanks as well, having served as Byng's orderly at the time. Unable to remember, Ollie leaves to confront Byng's daughter, Victoria.
Sources: en.wikipedia.org
May 13–15 – President Trump makes a state visit to China and meets with Chinese leader Xi Jinping. May 13 – The U.S. Senate confirms Kevin Warsh as the Chair of the Federal Reserve in a 54–45 vote. Warsh will succeed Jerome Powell at the end of the latter's term. May 14 Federal employees sue USDA and Secretary Brooke Rollins on First Amendment grounds over proselytizing Christian messaging in work emails. Mike Banks resigns as U.S. Border Patrol Chief, saying he wanted to spend time with family. Bank's resignation came weeks after the Washington Examiner alleged that he engaged in sex tourism in Colombia and Thailand. May 16 – 2026 Long Island Rail Road strike: Five unions representing over 3,500 workers for the Long Island Rail Road, the largest commuter rail system in North America, go on strike to negotiate a new contract with the Metropolitan Transportation Authority in New York City. May 18 – Five people, including two gunmen, are killed in a mass shooting at a mosque in San Diego, California. May 18–19 – The DOJ announces they reached a settlement with the Internal Revenue Service to resolve Trump's $10 billion lawsuit regarding the 2020 leak of his tax returns to The New York Times. Trump drops the lawsuit but will receive a $1.776 billion "anti-weaponization fund" to give to people who were prosecuted by the Biden administration. A day later, the DOJ reveals that the settlement terms include that the IRS is "forever barred and precluded" from investigating past tax returns filed by President Trump, his family and his businesses. May 19 – U.S.
Mick Jones – high-strung guitar (4) Pete Min – siren guitar (6) Jay Bellerose – drums (3) Duane LaVold – backing vocals (1) Neal Casal – backing vocals (9) The London Session Orchestra (Tracks 2, 5, 10 & 11)
==== Childhood ==== Thomas wrote a number of accounts of his childhood growing up in Swansea, and there are also accounts available by those who knew him as a young child. Thomas wrote several poems about his childhood and early teenage years, including "Once it was the colour of saying" and "The hunchback in the park", as well as short stories such as The Fight and A Child's Christmas in Wales. Thomas's four grandparents played no part in his childhood. For the first ten years or so of his life, Thomas's Swansea aunts and uncles helped with his upbringing. These were his mother's three siblings, Polly and Bob, who lived in the St Thomas district of Swansea and Theodosia, and her husband, the Rev. David Rees, in Newton, Swansea, where parishioners recall Thomas sometimes staying for a month or so at a time. All four aunts and uncles spoke Welsh and English. Thomas's childhood also featured regular summer trips to the Llansteffan peninsula, a Welsh-speaking part of Carmarthenshire. In the land between Llangain and Llansteffan, his mother's family, the Williamses and their close relatives, worked a dozen farms with over a thousand acres between them. The memory of Fernhill, a dilapidated 15-acre farm rented by his maternal aunt, Ann Jones, and her husband, Jim Jones, is evoked in the 1945 lyrical poem "Fern Hill", but is portrayed more accurately in his short story, The Peaches.
Sources: en.wikipedia.org
Dry powder is usually held frozen, shielded from light, and kept away from moisture. Desiccant packaging limits hydrolysis during storage. Solutions are typically aliquoted and frozen once, because repeated thawing shortens useful life.
Mass spectrometry establishes molecular mass, and reversed-phase chromatography reports purity. Peptide mapping or amino acid analysis supports sequence-level confirmation. No single technique covers all failure modes, so laboratories combine results.
Common entries include appearance, purity by chromatographic area, measured mass, and sometimes residual solvents or counter-ion content. Methods and instrument conditions are not always described. The document reflects the supplier's own testing unless an independent laboratory is named.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.